HemoShear Therapeutics has partnered with Pfizer to develop a predictive model for preclinical drug-induced vascular injury (DIVI). Financial terms of the multi-year deal were not disclosed. The initial stage of the collaboration was designed to assess the repeatability of vascular toxicities of a specifically chosen set of drugs in HemoShear’s REVEAL-Tx platform. In this next stage, the companies will use HemoShear’s platform to assess a large number of compounds with the aim of building a p...